An Update on Medical Therapy for Pulmonary Arterial Hypertension
Author:
Publisher
Springer Science and Business Media LLC
Subject
Internal Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11906-013-0394-8.pdf
Reference99 articles.
1. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.
2. •• Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140(2):301–9. The study reported that although the medical insurance system is insufficient in China, there is still a significant and rapid improvement in survival of PAH patients when the targeted therapies are employed, compared with that from 2007 registry.
3. •• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56. This registry includes more than 2,600 patients from 55 US centers, and is currently the largest survival registry worldwide. The study authoritatively suggests considerable improvements in survival in the past two decades since targeted medications for PAH were developed.
4. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–82.
5. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–8.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cysteine and glycine‐rich protein 2 promotes hypoxic pulmonary vascular smooth muscle cell proliferation through the Wnt3α‐β‐catenin/lymphoid enhancer‐binding factor 1 pathway;Journal of Biochemical and Molecular Toxicology;2022-06-13
2. Hypoxia‐inducible factor‐1 α deletion in myeloid lineage attenuates hypoxia‐induced pulmonary hypertension;Physiological Reports;2019-03-29
3. Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping;PLOS ONE;2017-01-04
4. A randomized double blinded placebo controlled trial of sildenafil for renoprotection prior to hilar clamping in patients undergoing robotic assisted laparoscopic partial nephrectomy;Journal of Surgical Oncology;2016-09-09
5. Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters;General physiology and biophysics;2016
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3